Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: BT-114143 Injection · Abnormal Uterine Bleeding Primary completion pushed from Sep 23, 2025 to Apr 28, 2026 ScinnoHub Pharmaceutical Co., Ltd.Phase 1 NCT07169214
  2. Notable: Paediatric Sleep Diagnosis Technology Primary and study completion dates pushed to Oct 14, 2027 Acurable Ltd.Not specified NCT04031950
  3. Notable: NeVa Retrospective Comparative SR Study Primary and study completion dates pushed to Feb 1, 2027 VesalioNot specified NCT06964724
  4. Notable: Neuralert Stroke Monitor Pilot Trial Primary completion pushed from May 1, 2026 to Nov 14, 2027 Neuralert Technologies LLCNot applicable NCT06368193
  5. Notable: KPAP vs EPR for Comfort Primary completion pushed from Dec 1, 2026 to Jul 1, 2027 SleepRes Inc.Not applicable NCT07530510
  6. Notable: KPAP vs AirSense 11 With EPR Primary completion pushed from Feb 1, 2027 to Dec 1, 2027 SleepRes Inc.Not applicable NCT07751562
  7. Notable: Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen · Adults and Adolescents With Tuberculous Meningitis Primary completion pushed from Apr 30, 2028 to Oct 1, 2029 National Institute of Allergy and Infectious Diseases (NIAID)Phase 2 NCT05383742
  8. Notable: Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil Primary completion pushed from May 30, 2026 to Dec 30, 2026 Spanish National Research CouncilNot applicable NCT06245616
  9. Notable: Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Primary completion pushed from Nov 1, 2026 to Mar 15, 2029 NRG OncologyPhase 3 NCT04134260
  10. Notable: PROmoting Pain Self-Management (PROs) Trial: Holistic Pain Care in the Military Health System Primary completion pushed from Jul 1, 2027 to Aug 1, 2028 Brooke Army Medical CenterNot applicable NCT06940986
  11. Notable: Vancomycin Taper to Prevent Recurrent Clostridioides Difficile Primary completion pushed from Jun 1, 2030 to Jul 1, 2031 McGill University Health Centre/Research Institute of the McGill University Health CentrePhase 3 NCT07328971
  12. Notable: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment · Metastatic (Stage IV) Breast Cancer Primary completion pushed from Jul 31, 2026 to Nov 30, 2027 University of MiamiPhase 2 NCT05826964
  13. Notable: Anticoagulation in Post MI LV Thrombus Trial in Nepal Primary and study completion dates pushed to Dec 2028 Shahid Gangalal National Heart CentrePhase 4 NCT05794399
  14. Notable: Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma Primary completion pushed from Jul 30, 2026 to Dec 30, 2027 Jiyan LiuPhase 2 NCT07054307
  15. Notable: Reduced Venetoclax Exposure Primary completion pushed from Oct 2026 to Oct 2027 Northwell HealthPhase 2 NCT07163793
  16. Notable: Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery Primary and study completion dates pushed to Jun 2029 Istanbul UniversityPhase 4 NCT06871787
  17. Notable: Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer Primary completion pushed from Dec 2025 to Dec 1, 2027 Jeeyun LeePhase 1/2 NCT06085755
  18. Notable: Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases Primary completion pushed from Apr 1, 2027 to Dec 20, 2027 University of Sao Paulo General HospitalPhase 4 NCT07341386
  19. Notable: Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer Primary completion pushed from Jul 2026 to Jul 1, 2027 St Vincent's Hospital, SydneyPhase 1/2 NCT04947189
  20. Notable: Combining Stellate Ganglion Block With Prolonged Exposure for PTSD Primary completion pushed from Mar 31, 2027 to Mar 31, 2028 The University of Texas Health Science Center at San AntonioPhase 2 NCT05889741
  21. Notable: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Primary completion pushed from May 31, 2024 to Feb 15, 2025 Cedars-Sinai Medical CenterPhase 4 NCT03417388
  22. Notable: Optimization of Post-transplantation Benadamustine and Cyclophosphamide · High-risk Myeloid Malignancies and a Partially Mismatched Donor Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027 St. Petersburg State Pavlov Medical UniversityPhase 2 NCT07238712
  23. Notable: [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression · Metastatic Breast Cancer Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 University of WashingtonPhase 1/2 NCT06502691
  24. Notable: Treatment of Social and Language Deficits With Leucovorin for Young · Autism Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027 Southwest Autism Research & Resource CenterPhase 2 NCT04060030
  25. Notable: Ketamine for Combined Depression and Alcohol Use Disorder Primary and study completion pushed from Jul 1, 2027 to Jul 1, 2028 University Hospital of North NorwayPhase 1/2 NCT06090422